RegulatoryAlerts Logo
RegulatoryAlerts
InsightsBlogPricingSign InStart Free Trial
All FDA (CDER) updates
FDA (CDER)
GUIDANCE DRAFT
E22 General Considerations for Patient Preference Studies
Published: 2/6/2026Detected: 3/20/2026

Summary preview

General considerations for conducting patient preference studies under FDA’s draft framework are intended to harmonize study design, analysis, and reporting expectations so that preference evidence can be used more…

Get the full analysis, free

Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.

Create free account
clinical
safety
labeling
quality
manufacturing
#patient preference
#stated preference
#choice-based
#benefit-risk
#clinical endpoints

Official Source Document
Source Verified

Access the original document directly from FDA CDER.

View Official Document

More from FDA (CDER)

  • E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility10/1/2026
  • Temporary Policies for Compounding Certain Starter Parenteral Nutrition Drug Products for Neonates: Guidance for Industry9/8/2026
  • Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling9/2/2026
  • Evaluation of Therapeutic Equivalence8/21/2026
  • Determining Whether to Submit an ANDA or a 505(b)(2) Application8/17/2026

Get FDA (CDER) alerts in your inbox as they are published.

Free plan, 2-minute setup, no credit card required.

RegulatoryAlerts Logo
RegulatoryAlerts

Automated regulatory intelligence monitoring for pharmaceutical and biotech professionals. Track FDA, EMA, and Health Canada updates seamlessly.

Product

  • Insights
  • Updates by Therapeutic Area
  • FDA Updates
  • EMA Updates
  • Pricing
  • Features
  • Request Demo

Resources

  • Integration Guides
  • Regulatory Glossary
  • EMA Timeline
  • Best Practices
  • Therapeutic Areas

Company

  • About Us
  • Blog
  • Contact
  • Security
  • Privacy Policy
  • Terms of Service

    • © 2026 RegulatoryAlerts. All rights reserved.

    Not affiliated with the FDA, EMA, or Health Canada.